A Randomized, Double Blind, Placebo-Controlled, Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism [confirmed morning testosterone (T) ≤300 ng/dL] following a 6 month diet and 15 month exercise program.

开始日期2016-01-11

申办/合作机构

Repros Therapeutics, Inc.

NCT02274181

/ Completed临床1期

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

The purpose of this study is to investigate the route(s) of elimination and mass balance of enclomiphene after oral administration of a single 25 mg (approximately equivalent to [(
]) 500 nanocurie [nCi]) dose of [14C]Androxal in healthy adult male subjects.

开始日期2014-12-01

申办/合作机构

Repros Therapeutics, Inc.

[+1]

NCT02160704

/ Withdrawn临床2/3期IIT

PHASE 2b RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY STUDY TO EVALUATE THE EFFICACY OF ANDROXAL IN IDIOPATHIC MALE INFERTILITY (PROTOCOL #01-14-40-08)

This is an exploratory, single center, randomized, parallel, double-blind placebo- and active-controlled trial in adult males ages 18 to 35 years of age who have male infertility of unknown cause. Approximately 50 men will be randomly assigned to one of two treatment groups according to a 1:1 ratio. About half of the men will receive 25mg Androxal and half of the men will receive a placebo (non-active pill) for 16 weeks. This study will last approximately 4 months and involve up to 7 visits.
The purpose of this study is to determine the effect the Androxal on sperm production.

开始日期2014-09-22

申办/合作机构

Baylor College of Medicine

100 项与恩氯米芬相关的临床结果

登录后查看更多信息

100 项与恩氯米芬相关的转化医学

登录后查看更多信息

100 项与恩氯米芬相关的专利（医药）

登录后查看更多信息

217

项与恩氯米芬相关的文献（医药）

2024-12-01·SCIENCE OF THE TOTAL ENVIRONMENT

Chemical profiling of organic contaminants in rural surface waters combining target and non-target LC-HRMS/MS analysis

Article

作者: Martínez-Piernas, Ana B. ; Moreno-González, David ; García-Reyes, Juan F. ; Gilbert-López, Bienvenida ; Fernández-García, Alfonso ; Martínez-Piernas, Ana B ; García-Reyes, Juan F

The pollution of natural waters by contaminants of emerging concern (CECs) is one of the pressing problems due to their global distribution and potential negative effects on the environment and human health. In rural areas with lower population density and limited industrial development, less contamination is expected. However, the lack of wastewater treatment plants (WWTPs) or their poor removal efficiency can lead to significant input of pollutants. In this context, 11 streams of rural areas in the Guadalquivir River basin, southeast of Spain, were studied over two years to obtain an overview of the origin and distribution of contaminants. A target method using solid-phase extraction and liquid chromatography coupled to high resolution mass spectrometry (LC-HRMS) was developed for the analysis of 316 compounds in surface waters. A total of 78 target analytes were detected, comprising pesticides, pharmaceuticals, personal care products (PCPs), transformation products (TPs), and industrial chemicals. The flame retardant tributyl phosphate (16-3572 ng L^-1) was detected in all samples, followed by caffeine (30-8090 ng L^-1) and the analgesic tramadol (3-1493 ng L^-1). The target approach was combined with a non-target analysis (NTA) strategy to obtain an overall perspective of the chemical profile of unexpected or unknown compounds in the samples. Up to 79 contaminants were tentatively identified, and 12 of them were finally confirmed with standards. Most of the contaminants determined by NTA were pharmaceuticals and their TPs. The results indicated that most of CECs have an urban origin despite traditional agriculture is the main economic activity in this region. Moreover, the absence of WWTPs in small towns is significant, as contamination levels at these sites were comparable to or higher than those in larger populations with sewage treatments.

2024-09-01·Translational Andrology and Urology

Safety and efficacy of enclomiphene and clomiphene for hypogonadal men

Article

作者: Saffati, Gal ; Kronstedt, Shane ; Hinojosa-Gonzalez, David E ; Lipshultz, Larry I. ; Orozco Rendon, Daniela ; Hinojosa-Gonzalez, David E. ; Kassab, Jordan ; Khera, Mohit ; Lipshultz, Larry I

Background:

Both clomiphene citrate and its isomer, enclomiphene, have become widespread within urologic practice; thus, understanding these medications' comparative benefits and risks is crucial for optimizing treatment and providing improved therapeutic options. We sought to investigate the longitudinal benefits and risks associated with enclomiphene, compared to clomiphene, and to provide valuable insights for clinicians when making treatment decisions in the management of hypogonadism.

Methods:

We retrospectively studied patients at our academic center who had been prescribed clomiphene and, later, enclomiphene for hypogonadism. Baseline laboratory values were documented for each patient before being prescribed clomiphene, followed by subsequent values for each variable in the most recent visit before stopping clomiphene and any noted adverse effects experienced during this time. The same process was repeated for enclomiphene, using the clomiphene levels as an updated baseline. Two-tailed t-tests were employed using R to analyze the longitudinal impacts of clomiphene and enclomiphene on serum hormone values as well as a regression analysis to estimate the odds ratio (OR) for adverse events between the two therapies.

Results:

Among 66 patients, enclomiphene exhibited a median testosterone increase of 166 (vs. 98 ng/dL, P=0.20) with lower estradiol change than clomiphene (-5.92 vs. 17.50 pg/mL, P=0.001). Adverse effects were statistically significantly less frequent with enclomiphene, including decreased libido (P=0.001), reduced energy (P=0.044), and mood changes (P=0.03). Regression analysis confirmed lower odds of adverse events with enclomiphene [OR: 0.18; 95% confidence interval (CI): 0.07-0.44, P=0.02].

Conclusions:

Our findings demonstrate that enclomiphene provides improvement in testosterone levels with a lower rate of documented adverse events. These findings support enclomiphene as a comparable treatment option for hypogonadal men while minimizing the risk of adverse effects. Further research and more extensive studies are warranted to validate these conclusions and explore the additional long-term effects of enclomiphene to guide future patient counseling regarding these medications.

2023-11-01·Plastic surgery (Oakville, Ont.)

Clomiphene Citrate and Enclomiphene Hydrochloride Exposure Is Associated With Interfrontal Suture Fusion in Zebrafish

Article

作者: Bezuhly, Michael ; Franz-Odendaal, Tamara A.

Background: The last several decades have witnessed an increase in metopic craniosynostosis incidence. Population-based studies suggest that pharmacological exposure in utero may be responsible. This study examined effects of the fertility drug clomiphene citrate (CC) on calvarial development in an established model for craniofacial development, the zebrafish Danio rerio. Results: Zebrafish larvae were exposed to clomiphene citrate or its isomer enclomiphene for five days at key points during calvarial development. Larvae were then raised to adulthood in normal rearing water. Zebrafish were analyzed using whole-mount skeletal staining. We observed differential effects on survivability, growth and suture formation depending on the treatment. Treatments with CC or enclomiphene at 5.5 mm SL led to increased fusion of the interfrontal suture (p < .01) compared to controls. Conclusions: Exposure to fertility drugs appears to affect development of the cranial vault, specifically the interfrontal suture, in zebrafish. Further research is required to identify the signaling mechanisms at play. This work suggests that fertility drug treatment may contribute to the increased incidence of metopic craniosynostosis observed globally.

项与恩氯米芬相关的新闻（医药）

2025-07-30

·EINPresswire

MOPE Clinic Highlights Clomiphene/Enclomiphene as Innovative Alternatives to Testosterone Replacement Therapy for Men

The Pros and Cons of Boosting Natural Testosterone Production with Selective Estrogen Receptor Modulators (SERMs) Clomiphene and Enclomiphene represent a revolutionary shift in how we manage low testosterone in men through enhancing the body’s natural hormone production as an alternative to traditional TRT.” — Chris Rue, FNP-C METAIRIE, LA, UNITED STATES, July 30, 2025 / EINPresswire.com / -- Metairie, LA– As the conversation around men’s hormonal health continues to grow, MOPE Clinic and Chris Rue, FNP-C are helping to lead the way in providing evidence-based options for testosterone optimization. One of the most compelling developments in this area is the use of medications like Clomiphene citrate and Enclomiphene citrate to stimulate the body’s own production of testosterone. These compounds, known as Selective Estrogen Receptor Modulators (SERMs), have gained popularity among men looking for an alternative to traditional testosterone replacement therapy (TRT). At MOPE Clinic, patients receive personalized, safe, and medically supervised hormone care tailored to their unique needs. What Are Clomiphene and Enclomiphene? Clomiphene citrate is a well-known fertility medication that has long been used in women. However, in recent years, it has found an important place in men’s health care. Enclomiphene, its purified isomer, has emerged as a more targeted treatment option with fewer estrogenic side effects. Both medications work by blocking estrogen receptors in the hypothalamus. This action tricks the brain into thinking estrogen levels are low, which leads to an increase in gonadotropin-releasing hormone (GnRH). In turn, GnRH stimulates the pituitary gland to produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones tell the testes to produce more testosterone and sperm. In other words, Clomiphene and Enclomiphene help reactivate the body’s natural testosterone production—a critical distinction from TRT, which replaces testosterone from external sources and often shuts down the body’s own production. The Benefits of Clomiphene and Enclomiphene At MOPE Clinic, Chris Rue, FNP-C emphasizes a holistic, functional approach to hormone optimization. In that light, Clomiphene and Enclomiphene offer several unique advantages: 1. Preservation of Fertility Unlike TRT, which can suppress sperm production, Clomiphene and Enclomiphene support spermatogenesis. This makes them ideal for younger men or those planning to maintain fertility while improving their testosterone levels. 2. Endogenous Testosterone Production These SERMs stimulate the body’s own production of testosterone. This avoids the testicular shrinkage and hypothalamic-pituitary-testicular axis (HPTA) suppression commonly seen with TRT. 3. Oral Administration Clomiphene and Enclomiphene are taken orally, typically as a pill taken daily or several times per week. This is more convenient than injections, gels, or pellets required in most TRT protocols. 4. Lower Risk of Erythrocytosis TRT can increase red blood cell count, raising the risk of blood clots. Clomiphene and Enclomiphene pose a lower risk for this complication. 5. Fewer Legal and Regulatory Concerns Clomiphene and Enclomiphene are not classified as controlled substances in the United States. This makes prescribing and accessing them more straightforward for both providers and patients. Who Is a Good Candidate? According to Chris Rue, FNP-C, ideal candidates for Clomiphene or Enclomiphene therapy include: Men under age 50 experiencing symptoms of low testosterone (fatigue, low libido, mood changes, etc.) Patients who still want to preserve fertility Individuals hesitant to start long-term TRT Men with secondary hypogonadism, where the problem lies in the brain or pituitary, not the testes At MOPE Clinic, patients undergo comprehensive lab testing, physical exams, and hormone assessments to determine whether Clomiphene or Enclomiphene is an appropriate treatment option. What Are the Limitations? Despite their many benefits, Clomiphene and Enclomiphene are not perfect solutions for every patient. At MOPE Clinic, education and transparency are key. Here are the primary limitations patients should consider: 1. Not Effective for Primary Hypogonadism If the testes are damaged or unresponsive (primary hypogonadism), Clomiphene and Enclomiphene won’t help. These medications require a functioning hypothalamic-pituitary-testicular axis. 2. Estrogenic Side Effects (Clomiphene) Some men experience visual disturbances, mood swings, or gynecomastia (breast tissue development) due to the mixed estrogenic effects of Clomiphene. Enclomiphene, being the purified isomer, generally causes fewer of these issues. 3. Variable Response Not all men respond the same. Some may see only modest increases in testosterone or symptom improvement. Ongoing monitoring is essential. 4. Off-Label Use Currently, neither Clomiphene nor Enclomiphene is FDA-approved specifically for male hypogonadism. However, off-label use is common and backed by numerous clinical studies. 5. Requires Patience and Follow-Up Clomiphene and Enclomiphene require several weeks to months to fully evaluate effectiveness. Frequent follow-up lab testing is necessary to track LH, FSH, estradiol, and testosterone levels. Research and Clinical Evidence Clinical studies have demonstrated the efficacy of Clomiphene citrate in raising testosterone levels in men with secondary hypogonadism. One study published in Fertility and Sterility showed that Clomiphene increased serum testosterone from an average of 247 ng/dL to 610 ng/dL after 3 months of therapy ( https://pubmed.ncbi.nlm.nih.gov/16422830/ } Another study in The Journal of Urology found that Enclomiphene significantly increased testosterone levels while maintaining sperm production—something not typically seen with TRT ( https://pubmed.ncbi.nlm.nih.gov/26496621/ ) MOPE Clinic’s Personalized Approach At MOPE Clinic, Chris Rue, FNP-C ensures that every patient receives a tailored treatment plan that considers hormonal balance, lifestyle, nutrition, and long-term health. Rather than treating labs alone, the clinic focuses on relieving symptoms, restoring well-being, and preserving function. Patients receive ongoing support, education, and adjustments to therapy as needed. Whether you’re struggling with fatigue, weight gain, low libido, or brain fog, MOPE Clinic offers a comprehensive, patient-first approach to hormonal health. Conclusion: A Modern Option for a Modern Man Clomiphene and Enclomiphene represent a revolutionary shift in how we manage low testosterone in men. By enhancing the body’s natural hormone production, these medications provide a compelling alternative to conventional testosterone replacement therapy. Still, they are not without limitations. At MOPE Clinic, men can expect evidence-based guidance, thorough evaluations, and compassionate care that respects their goals—whether that’s reclaiming energy, improving libido, or preserving fertility. Schedule a Consultation Today Men interested in learning whether Clomiphene or Enclomiphene is right for them can schedule a consultation at MOPE Clinic with Chris Rue, FNP-C. About MOPE Clinic MOPE Clinic is a leading hormone optimization and wellness center dedicated to improving men’s and women’s health through personalized, research-backed care. Led by Chris Rue, FNP-C, the clinic specializes in testosterone optimization, peptide therapy, weight loss solutions, and integrative functional medicine. Chris Rue Metairie Optimal Performance Enhancement +1 504-265-5491 email us here Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床结果

2025-06-17

·EINPresswire

Perform Medical Launches Comprehensive Hormone Balancing Program for Men and Women in the Greater Charleston Area

SUMMERVILLE, SC, UNITED STATES, June 17, 2025 / EINPresswire.com / -- Perform Medical , a premier wellness clinic serving the Lowcountry, proudly announces the launch of its advanced, personalized hormone balancing programs for both men and women. Under the clinical leadership of Taylor Vaughan, Medical Director, MBA, and Kaley Morris, Physician Assistant, the initiative offers an integrative, results-driven approach to correcting hormonal imbalances that impact health, vitality, and quality of life. At Perform Medical, the mission is clear: Reclaim Your Health, Hormone by Hormone. With the understanding that hormone shifts are a natural part of aging, the clinic empowers patients to stop merely enduring the symptoms and instead regain their energy, clarity, and confidence through customized hormone therapy. Why Hormone Balance Matters Hormones govern nearly every system in the human body—from metabolism and mood to sexual health and mental clarity. When these powerful messengers fall out of sync, patients may experience symptoms such as: - Chronic fatigue and poor sleep - Weight gain and muscle loss - Mood swings, anxiety, and depression - Low libido and sexual dysfunction - Brain fog and poor concentration - Hot flashes and night sweats Whether the imbalance stems from aging, menopause, andropause, or chronic stress, Perform Medical’s team addresses the root causes with medical precision and compassionate care. Tailored Care for Men Men facing symptoms of low testosterone—such as reduced motivation, decreased muscle mass, erectile dysfunction, and mental fog—can benefit from Perform Medical’s Testosterone Replacement Therapy (TRT). The clinic offers multiple delivery options, including bio-identical hormone pellets, injections, and fertility-preserving alternatives like Clomiphene or Enclomiphene. Each program begins with advanced hormone panel testing and includes ongoing lab monitoring to ensure optimal, long-lasting results. Estrogen blockers are also available to help manage potential side effects, ensuring that each plan is customized to the individual’s goals and lifestyle. Empowering Women Through Every Life Stage For women navigating perimenopause, menopause, or postmenopause, Perform Medical delivers cutting-edge bio-identical hormone replacement therapy (BHRT) to alleviate hot flashes, mood instability, low libido, and more. Led by Kaley Morris, PA-C, the women’s program includes pellet therapy, topical hormone creams, and integrated wellness support to restore balance naturally and effectively. The clinic’s BHRT pellets—plant-based and structurally identical to human hormones—offer long-term, steady-release dosing without the daily hassle of pills or creams. They are a preferred option for women seeking consistent relief and convenience. The Perform Medical Difference Perform Medical stands out for its deep specialization in hormonal health, evidenced by: - Expert Clinicians: Board-certified providers with advanced training in hormone therapy - Individualized Care Plans: No cookie-cutter protocols—just precision medicine based on lab data and symptoms - Local Support: A patient-first approach rooted in the Charleston community - Whole-Body Wellness: Hormone therapy integrated with sexual wellness, medical weight loss, and functional health programs Now Serving the Greater Charleston Area Perform Medical is currently welcoming patients from Summerville, Charleston, Mount Pleasant, Daniel Island, Isle of Palms, Sullivans Island, Kiawah Island, Moncks Corner, Goose Creek, and North Charleston. Is Hormone Therapy Right for You? If you’ve asked yourself questions like: - “Why am I tired all the time?” - “Is there a better way to handle menopause?” - “What can I do about brain fog and low libido?” - “Where can I get testosterone therapy in Charleston?” …it may be time to explore your hormonal health. To learn more or schedule their personalized hormone consultation, individuals can contact Perform Medical today at (843) 278-8474. About Perform Medical Perform Medical is a functional wellness clinic based in Charleston, SC, specializing in hormone health, sexual wellness, regenerative medicine, and medical weight loss. Led by Dr. Taylor Vaughan and Kaley Morris, PA-C, the clinic is dedicated to restoring health through advanced diagnostics, evidence-based therapies, and compassionate care. Taylor Vaughan, MD, MBA Perform Medical +1 843-278-8474 email us here Visit us on social media: Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

高管变更

100 项与恩氯米芬相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10876	-	-	DB06735

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
性腺机能减退	申请上市	欧盟	Renable Pharma Ltd.	2018-01-25
代谢性骨病	临床3期	美国	Repros Therapeutics, Inc.	2012-09-01
特发性低促性腺素性功能减退症	临床3期	美国	Repros Therapeutics, Inc.	2012-08-01
超重	临床3期	美国	Repros Therapeutics, Inc.	2012-08-01
继发性睾丸衰竭	临床3期	美国	Repros Therapeutics, Inc.	2006-03-01
不孕	临床3期	美国	Ferring BV	2005-02-01
肥胖	临床2期	美国	Repros Therapeutics, Inc.	2016-01-11
低睾酮水平	临床2期	美国	Repros Therapeutics, Inc.	2011-07-01
2型糖尿病	临床2期	美国	Repros Therapeutics, Inc.	2010-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02651688 (CTgov)	临床2期	特发性低促性腺素性功能减退症 \| 肥胖	50	Enclomiphene (Enclomiphene 12.5 mg)	窪構積願網淵鏇鬱簾獵(構簾顧糧廠蓋築觸遞鑰) = 淵簾憲膚齋夢憲網壓簾窪製選壓構鏇遞築製壓 (廠積襯糧餘淵獵願積衊, 7.08) 更多	-	2019-06-14
				Enclomiphene (Enclomiphene 25 mg)	窪構積願網淵鏇鬱簾獵(構簾顧糧廠蓋築觸遞鑰) = 壓衊齋獵製築簾鹹衊窪窪製選壓構鏇遞築製壓 (廠積襯糧餘淵獵願積衊, 7.88) 更多
NCT01386606 (CTgov)	临床2期	继发性睾丸衰竭	60	enclomiphene citrate (Androxal 6.25 mg)	觸簾壓淵壓網獵顧餘範(夢膚鹹顧餘蓋網範餘鑰) = 鏇選顧窪獵廠壓壓遞衊衊構構夢築鏇鏇齋製膚 (夢衊鹽鏇夢製網膚膚膚, 80.3) 更多	-	2015-09-23
				enclomiphene citrate (Androxal 12.5 mg)	觸簾壓淵壓網獵顧餘範(夢膚鹹顧餘蓋網範餘鑰) = 憲醖願範鏇築糧蓋鹽醖衊構構夢築鏇鏇齋製膚 (夢衊鹽鏇夢製網膚膚膚, 172.1) 更多
NCT01532414 (CTgov)	临床3期	继发性睾丸衰竭 \| 特发性低促性腺素性功能减退症 \| 超重	151	Placebo (Placebo)	鑰製鏇壓鹽範窪醖簾築 = 夢艱艱獵蓋襯餘鏇獵鏇繭繭鏇醖餘齋鹹鑰築簾 (窪憲構遞獵壓艱築壓築, 衊鹽鬱範廠糧顧窪憲顧 ~ 鬱製壓簾淵淵鬱顧構醖) 更多	-	2015-05-27
				Androxal (Androxal 12.5 mg)	繭夢繭選顧鏇膚製觸顧(築夢築壓鹽構鏇糧憲積) = 壓鑰衊繭憲築壓艱鏇願衊齋廠積簾壓範觸淵遞 (淵齋襯觸廠顧顧簾選廠, 觸鏇鏇憲艱艱艱衊窪衊 ~ 鑰製膚願鬱獵構範範遞) 更多
NCT01739595 (CTgov)	临床3期	继发性睾丸衰竭 \| 特发性低促性腺素性功能减退症 \| 超重	181	Placebo (Placebo)	夢製壓齋觸艱艱選構觸 = 窪鬱簾範獵繭範齋鏇網鏇選獵淵鹹鑰醖鬱衊願 (蓋醖鏇獵鹹獵範壓製構, 鑰糧衊鑰餘鹹範顧顧鹽 ~ 衊齋襯窪選選壓鹽醖醖) 更多	-	2015-05-27
				enclomiphene citrate (Androxal 12.5 mg)	鏇鬱憲廠觸蓋糧襯艱襯(鑰餘鏇遞鑰鏇蓋顧範廠) = 願築襯醖遞觸遞窪鬱蓋獵鹹醖網顧餘製醖網淵 (鹽鏇範餘鏇選夢壓鏇蓋, 窪築鑰糧選醖網淵積鹽 ~ 襯網鹽網醖壓襯鹽鹽築) 更多
NCT01959685 (CTgov)	临床1期	-	9	Androxal	鏇餘齋窪選遞夢構願簾(糧窪鑰簾壓鏇艱鏇範網) = 蓋憲壓襯簾醖襯廠繭膚襯糧衊鹽網築艱鬱憲鏇 (鹹製鏇製餘廠鹽鏇壓蓋, 3.1) 更多	-	2014-08-11
NCT01270841 (CTgov)	临床2期	继发性睾丸衰竭	83	Placebo (Placebo)	遞鏇壓糧鬱遞鹽製鑰衊(襯蓋鑰襯壓壓淵衊壓憲) = 餘鏇網憲顧廠鬱獵糧憲簾壓顧鬱齋鹹窪淵廠鑰 (蓋鏇鏇艱鑰壓膚衊淵選, 47.5) 更多	-	2014-07-28
				topical testosterone (Testim (Topical Testosterone))	遞鏇壓糧鬱遞鹽製鑰衊(襯蓋鑰襯壓壓淵衊壓憲) = 衊遞積蓋製壓鹹鹹壓餘簾壓顧鬱齋鹹窪淵廠鑰 (蓋鏇鏇艱鑰壓膚衊淵選, 292.3) 更多
NCT01191320 (CTgov)	临床2期	2型糖尿病 \| 继发性睾丸衰竭 \| 特发性低促性腺素性功能减退症	102	Placebo (Placebo)	齋淵襯鹹簾膚願壓齋遞(鏇築醖餘繭蓋範製鏇獵) = 鏇觸襯齋憲獵艱齋鹽網鏇願餘鹹廠廠簾夢艱齋 (鏇蓋蓋鹹選憲餘鹹獵構, 0.012) 更多	-	2014-07-24
				Androxal (Androxal 12.5 mg)	齋淵襯鹹簾膚願壓齋遞(鏇築醖餘繭蓋範製鏇獵) = 鹽築遞積壓顧鹹製鏇醖鏇願餘鹹廠廠簾夢艱齋 (鏇蓋蓋鹹選憲餘鹹獵構, 0.015) 更多
NCT01534208 (CTgov)	临床3期	继发性睾丸衰竭	499	Androxal (Androxal 12.5 mg)	醖積餘膚觸廠築廠觸鏇(鏇鏇窪鑰蓋顧餘顧鹽艱) = 顧糧遞鑰鹹壓衊簾艱遞憲觸餘觸壓糧壓鏇製襯 (製顧艱築鏇膚淵襯鏇壓, 141.4) 更多	-	2014-07-24
				Androxal (Androxal 25 mg)	醖積餘膚觸廠築廠觸鏇(鏇鏇窪鑰蓋顧餘顧鹽艱) = 廠齋窪餘衊壓鹽蓋糧獵憲觸餘觸壓糧壓鏇製襯 (製顧艱築鏇膚淵襯鏇壓, 154.7) 更多